Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14349571 | 0.80 | NPC1 (0.50) | CNR2 | |
| SCHEMBL27152577 | 0.71 | P4HA1 (0.53) | CNR2HDAC4HDAC6 | |
| SCHEMBL16543467 | 0.70 | RAB9A (0.61) | — | |
| SCHEMBL16115983 | 0.69 | CNR2 (0.65) | CNR2CNR1 | |
| SCHEMBL10146110 | 0.69 | KDM4E (0.42) | CNR2CNR1 | |
| SCHEMBL824021 | 0.68 | TSHR (0.32) | HDAC6 | |
| SCHEMBL16114727 | 0.67 | CNR2 (0.66) | CNR2CNR1 | |
| SCHEMBL14993359 | 0.66 | HDAC4 (0.56) | CNR2HDAC4HDAC6 | |
| SCHEMBL16115950 | 0.66 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL3873902 | 0.66 | HDAC4 (0.41) | CNR2HDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | GPBAR1, SLC10A1, NR1H4 | CNR2 485/4885HDAC4 1254/4885HDAC6 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.